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Abstract
Background: Tuberculosis remains a serious disease worldwide. Anti-tuberculosis campaigners
many times face negative tuberculin skin tests after Bacille Calmette Guérin vaccination. Increasing
tuberculin units might be a solution. However, is skin reaction a linear function of tuberculin dose?
Are there any side-effects when higher tuberculin doses are administered?
Case presentation: Six simultaneous Mantoux tuberculin skin tests, using 1, 2, 5, 10, 20, and 50
tuberculin units (88 altogether) of purified protein derivative RT23 per 0.1 mL were applied in a
healthy male Greek 35-years-old, with known natural Mycobacterium tuberculosis primary infection
since five years. Skin indurations 72 hours later were 15, 22, 23, 19, 23, and 27 mm respectively.
Conclusion: No linear relation between tuberculin dose and skin reaction observed; skin reaction
increased as tuberculin dose increased but with a decreasing rate, especially after 2 TUs, which
seem correctly defined for detection of natural infection. No side-effects occurred.
Background
During eighties the first author (ID), responsible for the
antituberculosis campaign in Ioannina prefecture, Greece,
faced negative post Bacille Calmette-Guérin (BCG) vacci-
nation tuberculin skin tests (TST) many times, and he had
to answer why. Was the BCG vaccine inadequate? Was the
inoculation technique inadequate? Was the usual tuber-
culin dose in TSTs, recommended for detection of the nat-
ural infection, also adequate for detection of the artificial
BCG-infection?
BCG contains weak bacilli; post-BCG TSTs may need
increased tuberculin doses. He increased tuberculin units
(TU) [1], supposing that the more the units are the more
the reaction is. However, this is not known. In addition,
are there any side-effects when higher tuberculin doses are
administered?
ID experimented on himself using simultaneously six dif-
ferent dilutions: 1, 2, 5, 10, 20, and 50 TUs per 0.1 mL (88
TUs altogether). None of the three relevant papers [2-4],
retrieved (22 May 2008) from Medline using the algo-
rithm (Mantoux OR Imotest OR Tine OR "tuberculin skin
test*" OR "tuberculin test*") AND (simultaneous* OR
multiple OR "same person" OR "same individual" OR
"same patient") AND (dose OR dosage OR unit* OR
"TU"), had used more than 15 TUs altogether simultane-
ously on the same person, compared to 88 TUs in our
case.
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Tuberculosis remains a serious disease that kills millions
worldwide [5-7], especially after human immunodefi-
ciency virus pandemic and worldwide emerging multid-
rug-resistant strains [6]; moreover it has come back, even
where we thought it was eliminated [8]. This self-experi-
ment has lost nothing of its value; contrarily it became
evergreen again. Tuberculosis specialists, practising physi-
cians, and immunity researchers might be interested on its
results.
Case presentation
Methods
In a healthy Greek male physician, 35-years-old, 173 cm
height, 72 Kg weight, never-smoker with no more than
one or two drinks weekly, with known natural infection
since five years, six TSTs were applied in 12 November
1985 (Figure 1). The hands belong to the first author, spe-
cialised in Pulmonology at Athens Thorax Diseases Hos-
pital 1976–1980. During this period he had repeatedly
negative Mantoux/Sokal TSTs; last negative 10 April 1980.
The first positive Mantoux occurred 20 June 1980.
Between 11 February 1980 and 11 April 1980 he had no
contact at all; thus the most probable period of infection
was between 11 and 20 April 1980, his first week in the
army, when there was contact with a very probable tuber-
culosis patient. He received chemoprophylaxis (300 mg
isoniazide and 25 mg pyridoxine every morning) from
July 1980 to May 1981.
Six simultaneous tuberculin skin tests on the same person (slightly retouched in 1 TU) Figure 1
Six simultaneous tuberculin skin tests on the same person (slightly retouched in 1 TU). The hands belong to a 
healthy Greek male 35, with known natural infection by Mycobacterium tuberculosis since 5 years (the first author). The six dots 
in the middle of erythemas represent the points of intradermal injection (Mantoux technique). The numbers between dots 
indicate the distance between injection points (in mm). The numbers under the heading 'TU' are the PPD-RT23 tuberculin 
units per injection (tuberculin dose). The numbers under the heading 'mm' are the induration diameters in mm. The small ver-
tical lines |...| show the induration boundaries, and the arrows towards these lines, transversely to the log axis of the forearm, 
point to the ballpoint traces made in order to find boundaries with Sokal's method.Cases Journal 2008, 1:115 http://www.casesjournal.com/content/1/1/115
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All vials of 1, 2, 5, 10, 20, 50 TU per 0.1 mL purified pro-
tein derivative (PPD) RT23 were provided by the Greek
Pasteur Institute on the same day, preserved under identi-
cal conditions, and administered within a few days after
production, long before their expiry date.
The tester was the domiciliary nurse of the Ioannina anti-
tuberculosis campaign, with more than twenty years of
experience. All six tests were injected lege-artis (one sharp
bevelled disposable 25 G needle with a plastic tuberculin
syringe per test; intradermal injection of exactly one tenth
of a millilitre of PPD tuberculin; 4 mm white blister).
Induration was read 72 hours later, using Sokal's tech-
nique (Figure 1).
Results
The results are presented in Figure 1. Skin reaction was not
a linear function of tuberculin dose; induration was
increased with a decreasing rate as tuberculin dose
increases (Figure 2), while an unexpected decrease
occurred in the dose of 10 TUs. Erythema (redness) was
not measured but it was parallel to induration (Figure 1).
No side-effects occurred.
Discussion
Declining increases have also found Tzimakas et al (1980;
four TSTs per person, 1, 2, 5, and 10 TUs PPD per 0.1 mL,
in Greek healthy men and tuberculosis patients; the last
ones had greater reactions) [9], Tzimakas et al (1984; 30
Greek healthy young women, of which ten were Mantoux
tested with 2, ten with 5 and ten with 10 TUs PPD-RT23
per 0.1 mL) [10], Dimoliatis (1987; either 1 or 2 or 10 TUs
PPD-RT23 per 0.1 mL Mantoux per group in 279 Greek
schoolage children vaccinated with either liquid or
lyophilized BCG; 6 groups) [1], Alcaide et al (1992; two
Mantoux, 2 and 5 TUs PPD-RT23, in 2575 Spanish indi-
viduals) [2], Stuart et al (2000; two TSTs per person, 5 and
10 TUs PPD per 0.1 mL, in 128 Australian health care
workers) [3], and Jentoft et al (2001; induration ≥ 15 mm
in 32% and 41% of the Mantoux tests with 2 and 5 TUs
PPD-RT23 respectively, in Norway) [4]. Tzimakas et al
(1980) [9] and Stuart et al (2000) [3] do not clarify the
strain of PPD used; perhaps PPD-RT23 and PPD-S respec-
tively, since PPD-RT23 is used in Greece and probably
PPD-S in Australia.
The paradox of lower induration at 10 TUs comparing to
5 TUs (Figure 2) may be due to chance, technique errors,
insufficient concentration in this particular vial, or
unknown factor(s). We do not believe that technique
errors occurred (same highly experienced tester, same
time, exactly 0.1 mL/test, identical blister per test, identi-
cal vial preservation conditions). Chance is highly
improbable because the phenomenon was observed again
a few days later (November 1985), when 431 children,
previously vaccinated with lyophilized BCG (April 1985),
were Mantoux tested using the same vials and found the
same pattern, in particular a mean diameter in mm 5.8
(standard deviation 4.8) in 74 children tested with 1 TU,
9.3 (4.4) in 15 with 2 TUs, 10.9 (5.7) in 88 with 5 TUs,
10.0 (5.4) in 94 with 10 TUs, 11.4 (5.8) in 78 with 20
TUs, and 14.5 (4.9) in 82 with 50 TUs [11]. Thus the most
probable explanation is that something was wrong with
this particular 10 TUs batch. Tzimakas et al [9] and Stuart
et al [3] did not offer details on reaction sizes and PPD-
strain used respectively; thus it is impossible to check
whether our decrease in 10 TUs exists also in their data.
The main thought of researcher, when he dared the
import of so many TUs in his body (44 times the usual
TST dose, and 5 to 6 times the highest bibliography dose),
was that much more quantities of (not purified) mtb
derivatives should exist within the body of the tubercular,
and in addition in the lungs and not simply intrader-
mally. The absence of any side effect vindicated this
hypothesis. He was also based on the already use of
denser dilutions [1], where he concluded that the TST
reaction is not a linear function of the tuberculin dose, but
rather a decreasingly increasing relation, compatible with
the known in Immunology antigen-antibody curve [6].
This hypothesis was also confirmed with this self-experi-
ment: the skin reaction is an increasing function of the
tuberculin dose but with a decreasing rate, especially after
2 TUs. It is worth noting that because of this decreasing
rate the recommended dose for routine detection of the
Tuberculin skin test induration as a function of tuberculin  dose Figure 2
Tuberculin skin test induration as a function of tuber-
culin dose. Six simultaneous Mantoux tests, using 1, 2, 5, 10, 
20, and 50 TUs PPD-RT23 per 0.1 mL (see Figure 1).Publish with BioMed Central    and   every 
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natural infection has correctly been defined to be 2 TUs
PPD-RT23 per 0.1 mL: while the gain in mm of induration
is big until this dose, it is negligible beyond this.
This is a case report. However, these results were repeated
in six groups of children tested with the six vials used in
Figure 1[11], and are in accordance to other research [1-
4,9,10].
Conclusion
After six simultaneous Mantoux tuberculin skin tests with
1, 2, 5, 10, 20, and 50 TUs in a healthy male 35, i.e. after
simultaneous injection on the same person 44 times more
TUs than the usual TST dose of 2 TUs PPD-RT23, (i) no
side-effects occurred; (ii) no linear relation between tuber-
culin dose and skin reaction observed; the later increased
as tuberculin dose increased but with a decreasing rate,
especially after 2 TUs, which (iii) seem correctly defined
for detection of natural infection.
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